CME Presentations
MS Series
Presentations
Racial and Genetic Implications for MS Treatment Selection
Speakers: Lilyana Amezcua, MD, MS, FAAN, Associate Professor of NeurologyRobert K. Shin, MD, FANA, FAAN, Professor, Department of Neurology Duration: 60 minutes
Presented on: August 27, 2021
Treatment Approaches in MS: Criteria for Decision Making
Speakers: Lilyana Amezcua, MD, MS, FAAN, Associate Professor of NeurologyRobert K. Shin, MD, FANA, FAAN, Professor, Department of Neurology Duration: 30 minutes
Presented on: September 10, 2021
Management of MS in African Americans/Blacks
Speakers: Lilyana Amezcua, MD, MS, FAAN, Associate Professor of NeurologyRobert K. Shin, MD, FANA, FAAN, Professor, Department of Neurology Duration: 15 minutes
Presented on: September 10, 2021
Young Latina MS Patient and Family Planning
Speakers: Lilyana Amezcua, MD, MS, FAAN, Associate Professor of NeurologyRobert K. Shin, MD, FANA, FAAN, Professor, Department of Neurology Duration: 15 minutes
Presented on: September 10, 2021
CIS: Treating or Not Treating and with What?
Speakers: Lilyana Amezcua, MD, MS, FAAN, Associate Professor of NeurologyRobert K. Shin, MD, FANA, FAAN, Professor, Department of Neurology Duration: 15 minutes
Presented on: September 10, 2021
Speakers
Lilyana Amezcua, MD, MS, FAAN
Lilyana Amezcua, MD, MS, FAAN
Associate Professor of Neurology
Lilyana Amezcua, MD, MS, FAAN, is an associate professor of neurology and the fellowship program director at the University of Southern California (USC), Keck School of Medicine in Los Angeles. She is principal investigator on multiple clinical research projects and her research interests include defining racial/ethnic disparities and modifiable (environmental and sociocultural) from non-modifiable genetic factors involved in disease severity and progression of multiple sclerosis (MS). Dr Amezcua serves as an elected member to the NMSS medical advisory board, the American Academy of Neurology Quality Measures for MS, and the NIH NINDS Health Disparities Steering Committee. In 2015, she was recognized for her dedication with an induction into the NMSS Health Professionals Hall of Fame.
Robert K. Shin, MD, FANA, FAAN
Robert K. Shin, MD, FANA, FAAN
Professor, Department of Neurology
Robert K Shin, MD, FANA, FAAN, is a graduate of Yale University and received his medical degree from the University of Pennsylvania School of Medicine. He completed a neurology residency and fellowships in neuro-ophthalmology and multiple sclerosis at the Hospital of the University of Pennsylvania.
Dr. Shin is currently Professor of Neurology at MedStar Georgetown University Hospital and Director of the Georgetown Multiple Sclerosis and Neuroimmunology Center. Dr. Shin has a special interest in visual problems associated with multiple sclerosis and other demyelinating disorders, including optic neuritis and double vision.
CME Information
Jointly provided by Consortium of Multiple Sclerosis Centers (CMSC) and PlatformQ Health Education, LLC (PQHE).Racial and Genetic Implications for MS Treatment Selection
ACKNOWLEDGEMENT
This activity is supported by educational grants from Bristol Myers Squibb, Novartis Pharmaceuticals Corporation, and Sanofi Genzyme.TUITION
No fee is required for this programDATE OF RELEASE/EXPIRATION
Enduring Material
The enduring material will be available from August 27, 2021 to September 10, 2022TARGET AUDIENCE
This activity has been designed to meet the educational needs of physicians, pharmacists, nursing professionals, PAs, and other members of the healthcare team involved in the management of patients with MS.LEARNING OBJECTIVES
Upon completing this activity, participants should be better able to:- Summarize the impact of race and gender on MS presentation and disease course
- Explain how knowledge of race and gender issues can help guide treatment selection and approaches to care
- Develop strategies to discuss ongoing or currently enrolling trials as potential care options with patients of racial and ethnic minority groups
ACCREDITATION AND CREDIT DESIGNATION
In support of improving patient care, this activity has been planned and implemented by the Consortium of Multiple Sclerosis Centers (CMSC) and PlatformQ Health Education, LLC. CMSC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Physicians
The Consortium of Multiple Sclerosis Centers designates this enduring material for a maximum of 1 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.Nurses
The Consortium of Multiple Sclerosis Centers designates this enduring material for 1 contact hour (1.0 of these credits are in the area of pharmacology) of continuing education.Pharmacists
This knowledge-based activity (UAN JA4008165-9999-21-015-H01-P) qualifies for 1 contact hour (0.10 CEUs) of continuing pharmacy education credit.Physician Assistants (PAs)
The Consortium of Multiple Sclerosis Centers has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1 AAPA Category 1 CME credits. Approval is valid until September 10, 2022. PAs should only claim credit commensurate with the extent of their participation.Certificate of Attendance for Other Healthcare Professionals
A Certificate of Attendance will be given upon completion of course requirements enabling participants to register their credit with the appropriate licensing boards or associations. Participants may apply for other accreditations using procedures established by specific organizations.DISCLOSURE OF FINANCIAL RELATIONSHIPS
In accordance with the Accreditation Council for Continuing Medical Education’s (ACCME) Standards for Integrity and Independence in Continuing Education, CMSC and PQHE require that individuals in a position to control the content of an educational activity disclose all financial relationships with ineligible companies. CMSC and PQHE mitigate all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all their educational programs. Furthermore, CMSC and PQHE seek to verify that all scientific research referred to, reported, or used in a CE activity conforms to the generally accepted standards of experimental design, data collection, and analysis. CMSC and PQHE are committed to providing learners with high-quality CE activities that promote improvements in health care and not those of a commercial interest.
FACULTY DISCLOSURES
The program faculty reported the following relevant financial relationships that they have with ineligible companies:
Robert K. Shin, MD, FANA, FAAN served as faculty for this activity. He has received consulting fees from Biogen, Bristol Myers Squibb, EMD Serono, Genentech, Mallinckrodt, Novartis, and Sanofi Genzyme. He has served on the speaker’s bureau for Biogen, Bristol Myers Squibb, EMD Serono, Genentech, Mallinckrodt, Novartis, and Sanofi Genzyme.
Lilyana Amezcua, MD, MS, FAAN served as faculty for this activity. She has received consulting fees from EMD Serono and Genentech. She has served on the speaker’s bureau for Alexion. She has received research funds from Biogen and Genentech.
All of the relevant financial relationships listed for these individuals have been mitigated.STAFF DISCLOSURES
The planners, reviewers, editors, staff, or other members of CMSC who are in a position to control content have disclosed no relevant financial relationships.
The planners, reviewers, editors, staff, or other members of PlatformQ Health Education, LLC who are in a position to control content have disclosed no relevant financial relationships.MEDIA
InternetMETHOD OF PARTICIPATION
To successfully complete this activity, the participant must go to www.NeuroSeriesLive.com. To receive credit, participants must (1) read the activity front matter, (2) complete the educational activity online, and (3) complete the post-test and activity evaluation. To receive credit, participants must receive a minimum score of 70% on the post-testDISCLOSURE OF UNLABELED USE
CMSC and PQHE require faculty to disclose to the attendees when products or procedures being discussed are off-label, unlabeled, experimental, and/or investigational (not FDA approved); and any limitations on the information that is presented, such as data that are preliminary or that represent ongoing research, interim analyses, and/or unsupported opinion. Faculty in this activity may discuss information about pharmaceutical agents that is outside of US Food and Drug Administration approved labeling. This information is intended solely for continuing education and is not intended to promote off-label use of these medications. If you have questions, contact the medical affairs department of the manufacturer for the most recent prescribing information.DISCLAIMER
CMSC and PQHE present this information for educational purposes only. The content is provided solely by faculty who have been selected because of recognized expertise in their field. Participants have the professional responsibility to ensure that products are prescribed and used appropriately on the basis of their own clinical judgment and accepted standards of care. CMSC and PQHE, and the commercial supporter(s) assume no liability for the information herein.PRIVACY POLICY
Please review our privacy policy here: https://www.neuroserieslive.com/privacy-policy/.CONTACT INFORMATION
Accreditation and Technical Support:
For any technical issues or issues with your certificate, please contact NeuroSeriesLive at 877-394-1306 or at Support@NeuroSeriesLive.com.Jointly provided by Consortium of Multiple Sclerosis Centers (CMSC) and PlatformQ Health Education, LLC (PQHE).Management of MS in African Americans/Blacks
ACKNOWLEDGEMENT
This activity is supported by educational grants from Bristol Myers Squibb, Novartis Pharmaceuticals Corporation, and Sanofi Genzyme.TUITION
No fee is required for this programDATE OF RELEASE/EXPIRATION
Enduring Material
Management of MS in African Americans/Blacks
The enduring material will be available from September 10, 2021 to September 10, 2022TARGET AUDIENCE
This activity has been designed to meet the educational needs of physicians, pharmacists, nursing professionals, PAs, and other members of the healthcare team involved in the management of patients with MS.LEARNING OBJECTIVES
Upon completing this activity, participants should be better able to:- Consider patient’s disease activity, patient factors, and treatment goals and preferences to identify patient populations and scenarios in which high-efficacy DMTs are appropriate
- Assess recent data on the impact of DMTs on cognition in MS
ACCREDITATION AND CREDIT DESIGNATION
In support of improving patient care, this activity has been planned and implemented by the Consortium of Multiple Sclerosis Centers (CMSC) and PlatformQ Health Education, LLC. CMSC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Physicians
The Consortium of Multiple Sclerosis Centers designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.Nurses
The Consortium of Multiple Sclerosis Centers designates this enduring material for 0.25 contact hours (0.25 of these credits are in the area of pharmacology) of continuing education.Pharmacists
This knowledge-based activity (UAN JA4008165-9999-21-011-H01-P) qualifies for 0.25 contact hour (0.025 CEUs) of continuing pharmacy education credit.Physician Assistants (PAs)
The Consortium of Multiple Sclerosis Centers has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.25 AAPA Category 1 CME credits. Approval is valid until September 10, 2022. PAs should only claim credit commensurate with the extent of their participation.Certificate of Attendance for Other Healthcare Professionals
A Certificate of Attendance will be given upon completion of course requirements enabling participants to register their credit with the appropriate licensing boards or associations. Participants may apply for other accreditations using procedures established by specific organizations.DISCLOSURE OF FINANCIAL RELATIONSHIPS
In accordance with the Accreditation Council for Continuing Medical Education’s (ACCME) Standards for Integrity and Independence in Continuing Education, CMSC and PQHE require that individuals in a position to control the content of an educational activity disclose all financial relationships with ineligible companies. CMSC and PQHE mitigate all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all their educational programs. Furthermore, CMSC and PQHE seek to verify that all scientific research referred to, reported, or used in a CE activity conforms to the generally accepted standards of experimental design, data collection, and analysis. CMSC and PQHE are committed to providing learners with high-quality CE activities that promote improvements in health care and not those of a commercial interest.
FACULTY DISCLOSURES
The program faculty reported the following relevant financial relationships that they have with ineligible companies:
Robert K. Shin, MD, FANA, FAAN served as faculty for this activity. He has received consulting fees from Biogen, Bristol Myers Squibb, EMD Serono, Genentech, Mallinckrodt, Novartis, and Sanofi Genzyme. He has served on the speaker’s bureau for Biogen, Bristol Myers Squibb, EMD Serono, Genentech, Mallinckrodt, Novartis, and Sanofi Genzyme.
Lilyana Amezcua, MD, MS, FAAN served as faculty for this activity. She has received consulting fees from EMD Serono and Genentech. She has served on the speaker’s bureau for Alexion. She has received research funds from Biogen and Genentech.
All of the relevant financial relationships listed for these individuals have been mitigated.STAFF DISCLOSURES
The planners, reviewers, editors, staff, or other members of CMSC who are in a position to control content have disclosed no relevant financial relationships.
The planners, reviewers, editors, staff, or other members of PlatformQ Health Education, LLC who are in a position to control content have disclosed no relevant financial relationships.MEDIA
InternetMETHOD OF PARTICIPATION
To successfully complete this activity, the participant must go to www.NeuroSeriesLive.com. To receive credit, participants must (1) read the activity front matter, (2) complete the educational activity online, and (3) complete the post-test and activity evaluation. To receive credit, participants must receive a minimum score of 70% on the post-testDISCLOSURE OF UNLABELED USE
CMSC and PQHE require faculty to disclose to the attendees when products or procedures being discussed are off-label, unlabeled, experimental, and/or investigational (not FDA approved); and any limitations on the information that is presented, such as data that are preliminary or that represent ongoing research, interim analyses, and/or unsupported opinion. Faculty in this activity may discuss information about pharmaceutical agents that is outside of US Food and Drug Administration approved labeling. This information is intended solely for continuing education and is not intended to promote off-label use of these medications. If you have questions, contact the medical affairs department of the manufacturer for the most recent prescribing information.DISCLAIMER
CMSC and PQHE present this information for educational purposes only. The content is provided solely by faculty who have been selected because of recognized expertise in their field. Participants have the professional responsibility to ensure that products are prescribed and used appropriately on the basis of their own clinical judgment and accepted standards of care. CMSC and PQHE, and the commercial supporter(s) assume no liability for the information herein.PRIVACY POLICY
Please review our privacy policy here: https://www.neuroserieslive.com/privacy-policy/.CONTACT INFORMATION
Accreditation and Technical Support:
For any technical issues or issues with your certificate, please contact NeuroSeriesLive at 877-394-1306 or at Support@NeuroSeriesLive.com.Jointly provided by Consortium of Multiple Sclerosis Centers (CMSC) and PlatformQ Health Education, LLC (PQHE).Young Latina MS Patient and Family Planning
ACKNOWLEDGEMENT
This activity is supported by educational grants from Bristol Myers Squibb, Novartis Pharmaceuticals Corporation, and Sanofi Genzyme.TUITION
No fee is required for this programDATE OF RELEASE/EXPIRATION
Enduring Material
Young Latina MS Patient and Family Planning
The enduring material will be available from September 10, 2021 to September 10, 2022TARGET AUDIENCE
This activity has been designed to meet the educational needs of physicians, pharmacists, nursing professionals, PAs, and other members of the healthcare team involved in the management of patients with MS.LEARNING OBJECTIVES
Upon completing this activity, participants should be better able to:- Consider patient’s disease activity, patient factors, and treatment goals and preferences to identify patient populations and scenarios in which high-efficacy DMTs are appropriate
- Implement strategies to address symptom management in patients with MS
ACCREDITATION AND CREDIT DESIGNATION
In support of improving patient care, this activity has been planned and implemented by the Consortium of Multiple Sclerosis Centers (CMSC) and PlatformQ Health Education, LLC. CMSC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Physicians
The Consortium of Multiple Sclerosis Centers designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.Nurses
The Consortium of Multiple Sclerosis Centers designates this enduring material for 0.25 contact hours (0.25 of these credits are in the area of pharmacology) of continuing education.Pharmacists
This knowledge-based activity (UAN JA4008165-9999-21-012-H01-P) qualifies for 0.25 contact hour (0.025 CEUs) of continuing pharmacy education credit.Physician Assistants (PAs)
The Consortium of Multiple Sclerosis Centers has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.25 AAPA Category 1 CME credits. Approval is valid until September 10, 2022. PAs should only claim credit commensurate with the extent of their participation.Certificate of Attendance for Other Healthcare Professionals
A Certificate of Attendance will be given upon completion of course requirements enabling participants to register their credit with the appropriate licensing boards or associations. Participants may apply for other accreditations using procedures established by specific organizations.DISCLOSURE OF FINANCIAL RELATIONSHIPS
In accordance with the Accreditation Council for Continuing Medical Education’s (ACCME) Standards for Integrity and Independence in Continuing Education, CMSC and PQHE require that individuals in a position to control the content of an educational activity disclose all financial relationships with ineligible companies. CMSC and PQHE mitigate all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all their educational programs. Furthermore, CMSC and PQHE seek to verify that all scientific research referred to, reported, or used in a CE activity conforms to the generally accepted standards of experimental design, data collection, and analysis. CMSC and PQHE are committed to providing learners with high-quality CE activities that promote improvements in health care and not those of a commercial interest.
FACULTY DISCLOSURES
The program faculty reported the following relevant financial relationships that they have with ineligible companies:
Robert K. Shin, MD, FANA, FAAN served as faculty for this activity. He has received consulting fees from Biogen, Bristol Myers Squibb, EMD Serono, Genentech, Mallinckrodt, Novartis, and Sanofi Genzyme. He has served on the speaker’s bureau for Biogen, Bristol Myers Squibb, EMD Serono, Genentech, Mallinckrodt, Novartis, and Sanofi Genzyme.
Lilyana Amezcua, MD, MS, FAAN served as faculty for this activity. She has received consulting fees from EMD Serono and Genentech. She has served on the speaker’s bureau for Alexion. She has received research funds from Biogen and Genentech.
All of the relevant financial relationships listed for these individuals have been mitigated.STAFF DISCLOSURES
The planners, reviewers, editors, staff, or other members of CMSC who are in a position to control content have disclosed no relevant financial relationships.
The planners, reviewers, editors, staff, or other members of PlatformQ Health Education, LLC who are in a position to control content have disclosed no relevant financial relationships.MEDIA
InternetMETHOD OF PARTICIPATION
To successfully complete this activity, the participant must go to www.NeuroSeriesLive.com. To receive credit, participants must (1) read the activity front matter, (2) complete the educational activity online, and (3) complete the post-test and activity evaluation. To receive credit, participants must receive a minimum score of 70% on the post-testDISCLOSURE OF UNLABELED USE
CMSC and PQHE require faculty to disclose to the attendees when products or procedures being discussed are off-label, unlabeled, experimental, and/or investigational (not FDA approved); and any limitations on the information that is presented, such as data that are preliminary or that represent ongoing research, interim analyses, and/or unsupported opinion. Faculty in this activity may discuss information about pharmaceutical agents that is outside of US Food and Drug Administration approved labeling. This information is intended solely for continuing education and is not intended to promote off-label use of these medications. If you have questions, contact the medical affairs department of the manufacturer for the most recent prescribing information.DISCLAIMER
CMSC and PQHE present this information for educational purposes only. The content is provided solely by faculty who have been selected because of recognized expertise in their field. Participants have the professional responsibility to ensure that products are prescribed and used appropriately on the basis of their own clinical judgment and accepted standards of care. CMSC and PQHE, and the commercial supporter(s) assume no liability for the information herein.PRIVACY POLICY
Please review our privacy policy here: https://www.neuroserieslive.com/privacy-policy/.CONTACT INFORMATION
Accreditation and Technical Support:
For any technical issues or issues with your certificate, please contact NeuroSeriesLive at 877-394-1306 or at Support@NeuroSeriesLive.com.Jointly provided by Consortium of Multiple Sclerosis Centers (CMSC) and PlatformQ Health Education, LLC (PQHE).CIS: Treating or Not Treating and with What?
ACKNOWLEDGEMENT
This activity is supported by educational grants from Bristol Myers Squibb, Novartis Pharmaceuticals Corporation, and Sanofi Genzyme.TUITION
No fee is required for this programDATE OF RELEASE/EXPIRATION
Enduring Material
CIS: Treating or Not Treating and with What?
The enduring material will be available from September 10, 2021 to September 10, 2022TARGET AUDIENCE
This activity has been designed to meet the educational needs of physicians, pharmacists, nursing professionals, PAs, and other members of the healthcare team involved in the management of patients with MS.LEARNING OBJECTIVES
Upon completing this activity, participants should be better able to:- Summarize current and emerging biomarkers in MS, their association with disease development and progression, and their role in making treatment decisions
- Assess recent data on the impact of DMTs on cognition in MS
ACCREDITATION AND CREDIT DESIGNATION
In support of improving patient care, this activity has been planned and implemented by the Consortium of Multiple Sclerosis Centers (CMSC) and PlatformQ Health Education, LLC. CMSC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Physicians
The Consortium of Multiple Sclerosis Centers designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.Nurses
The Consortium of Multiple Sclerosis Centers designates this enduring material for 0.25 contact hours (0.25 of these credits are in the area of pharmacology) of continuing education.Pharmacists
This knowledge-based activity (UAN JA4008165-9999-21-013-H01-P) qualifies for 0.25 contact hour (0.025 CEUs) of continuing pharmacy education credit.Physician Assistants (PAs)
The Consortium of Multiple Sclerosis Centers has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.25 AAPA Category 1 CME credits. Approval is valid until September 10, 2022. PAs should only claim credit commensurate with the extent of their participation.Certificate of Attendance for Other Healthcare Professionals
A Certificate of Attendance will be given upon completion of course requirements enabling participants to register their credit with the appropriate licensing boards or associations. Participants may apply for other accreditations using procedures established by specific organizations.DISCLOSURE OF FINANCIAL RELATIONSHIPS
In accordance with the Accreditation Council for Continuing Medical Education’s (ACCME) Standards for Integrity and Independence in Continuing Education, CMSC and PQHE require that individuals in a position to control the content of an educational activity disclose all financial relationships with ineligible companies. CMSC and PQHE mitigate all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all their educational programs. Furthermore, CMSC and PQHE seek to verify that all scientific research referred to, reported, or used in a CE activity conforms to the generally accepted standards of experimental design, data collection, and analysis. CMSC and PQHE are committed to providing learners with high-quality CE activities that promote improvements in health care and not those of a commercial interest.
FACULTY DISCLOSURES
The program faculty reported the following relevant financial relationships that they have with ineligible companies:
Robert K. Shin, MD, FANA, FAAN served as faculty for this activity. He has received consulting fees from Biogen, Bristol Myers Squibb, EMD Serono, Genentech, Mallinckrodt, Novartis, and Sanofi Genzyme. He has served on the speaker’s bureau for Biogen, Bristol Myers Squibb, EMD Serono, Genentech, Mallinckrodt, Novartis, and Sanofi Genzyme.
Lilyana Amezcua, MD, MS, FAAN served as faculty for this activity. She has received consulting fees from EMD Serono and Genentech. She has served on the speaker’s bureau for Alexion. She has received research funds from Biogen and Genentech.
All of the relevant financial relationships listed for these individuals have been mitigated.STAFF DISCLOSURES
The planners, reviewers, editors, staff, or other members of CMSC who are in a position to control content have disclosed no relevant financial relationships.
The planners, reviewers, editors, staff, or other members of PlatformQ Health Education, LLC who are in a position to control content have disclosed no relevant financial relationships.MEDIA
InternetMETHOD OF PARTICIPATION
To successfully complete this activity, the participant must go to www.NeuroSeriesLive.com. To receive credit, participants must (1) read the activity front matter, (2) complete the educational activity online, and (3) complete the post-test and activity evaluation. To receive credit, participants must receive a minimum score of 70% on the post-testDISCLOSURE OF UNLABELED USE
CMSC and PQHE require faculty to disclose to the attendees when products or procedures being discussed are off-label, unlabeled, experimental, and/or investigational (not FDA approved); and any limitations on the information that is presented, such as data that are preliminary or that represent ongoing research, interim analyses, and/or unsupported opinion. Faculty in this activity may discuss information about pharmaceutical agents that is outside of US Food and Drug Administration approved labeling. This information is intended solely for continuing education and is not intended to promote off-label use of these medications. If you have questions, contact the medical affairs department of the manufacturer for the most recent prescribing information.DISCLAIMER
CMSC and PQHE present this information for educational purposes only. The content is provided solely by faculty who have been selected because of recognized expertise in their field. Participants have the professional responsibility to ensure that products are prescribed and used appropriately on the basis of their own clinical judgment and accepted standards of care. CMSC and PQHE, and the commercial supporter(s) assume no liability for the information herein.PRIVACY POLICY
Please review our privacy policy here: https://www.neuroserieslive.com/privacy-policy/.CONTACT INFORMATION
Accreditation and Technical Support:
For any technical issues or issues with your certificate, please contact NeuroSeriesLive at 877-394-1306 or at Support@NeuroSeriesLive.com.Jointly provided by Consortium of Multiple Sclerosis Centers (CMSC) and PlatformQ Health Education, LLC (PQHE).Treatment Approaches in MS: Criteria for Decision Making
ACKNOWLEDGEMENT
This activity is supported by educational grants from Bristol Myers Squibb, Novartis Pharmaceuticals Corporation, and Sanofi Genzyme.TUITION
No fee is required for this programDATE OF RELEASE/EXPIRATION
Enduring Material
Treatment Approaches in MS: Criteria for Decision Making
The enduring material will be available from September 10, 2021 to September 10, 2022TARGET AUDIENCE
This activity has been designed to meet the educational needs of physicians, pharmacists, nursing professionals, PAs, and other members of the healthcare team involved in the management of patients with MS.LEARNING OBJECTIVES
Upon completing this activity, participants should be better able to:- Summarize current and emerging biomarkers in MS, their association with disease development and progression, and their role in making treatment decisions
- Apply current evidence about long-term safety and efficacy outcomes of treatment with high-efficacy DMTs in patients with relapsing and progressive forms of MS
ACCREDITATION AND CREDIT DESIGNATION
In support of improving patient care, this activity has been planned and implemented by the Consortium of Multiple Sclerosis Centers (CMSC) and PlatformQ Health Education, LLC. CMSC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Physicians
The Consortium of Multiple Sclerosis Centers designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.Nurses
The Consortium of Multiple Sclerosis Centers designates this enduring material for 0.5 contact hours (0.5 of these credits are in the area of pharmacology) of continuing education.Pharmacists
This knowledge-based activity (UAN JA4008165-9999-21-010-H01-P) qualifies for 0.5 contact hour (0.05 CEUs) of continuing pharmacy education credit.Physician Assistants (PAs)
The Consortium of Multiple Sclerosis Centers has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.5 AAPA Category 1 CME credits. Approval is valid until September 10, 2022. PAs should only claim credit commensurate with the extent of their participation.Certificate of Attendance for Other Healthcare Professionals
A Certificate of Attendance will be given upon completion of course requirements enabling participants to register their credit with the appropriate licensing boards or associations. Participants may apply for other accreditations using procedures established by specific organizations.DISCLOSURE OF FINANCIAL RELATIONSHIPS
In accordance with the Accreditation Council for Continuing Medical Education’s (ACCME) Standards for Integrity and Independence in Continuing Education, CMSC and PQHE require that individuals in a position to control the content of an educational activity disclose all financial relationships with ineligible companies. CMSC and PQHE mitigate all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all their educational programs. Furthermore, CMSC and PQHE seek to verify that all scientific research referred to, reported, or used in a CE activity conforms to the generally accepted standards of experimental design, data collection, and analysis. CMSC and PQHE are committed to providing learners with high-quality CE activities that promote improvements in health care and not those of a commercial interest.
FACULTY DISCLOSURES
The program faculty reported the following relevant financial relationships that they have with ineligible companies:
Robert K. Shin, MD, FANA, FAAN served as faculty for this activity. He has received consulting fees from Biogen, Bristol Myers Squibb, EMD Serono, Genentech, Mallinckrodt, Novartis, and Sanofi Genzyme. He has served on the speaker’s bureau for Biogen, Bristol Myers Squibb, EMD Serono, Genentech, Mallinckrodt, Novartis, and Sanofi Genzyme.
Lilyana Amezcua, MD, MS, FAAN served as faculty for this activity. She has received consulting fees from EMD Serono and Genentech. She has served on the speaker’s bureau for Alexion. She has received research funds from Biogen and Genentech.
All of the relevant financial relationships listed for these individuals have been mitigated.STAFF DISCLOSURES
The planners, reviewers, editors, staff, or other members of CMSC who are in a position to control content have disclosed no relevant financial relationships.
The planners, reviewers, editors, staff, or other members of PlatformQ Health Education, LLC who are in a position to control content have disclosed no relevant financial relationships.MEDIA
InternetMETHOD OF PARTICIPATION
To successfully complete this activity, the participant must go to www.NeuroSeriesLive.com. To receive credit, participants must (1) read the activity front matter, (2) complete the educational activity online, and (3) complete the post-test and activity evaluation. To receive credit, participants must receive a minimum score of 70% on the post-testDISCLOSURE OF UNLABELED USE
CMSC and PQHE require faculty to disclose to the attendees when products or procedures being discussed are off-label, unlabeled, experimental, and/or investigational (not FDA approved); and any limitations on the information that is presented, such as data that are preliminary or that represent ongoing research, interim analyses, and/or unsupported opinion. Faculty in this activity may discuss information about pharmaceutical agents that is outside of US Food and Drug Administration approved labeling. This information is intended solely for continuing education and is not intended to promote off-label use of these medications. If you have questions, contact the medical affairs department of the manufacturer for the most recent prescribing information.DISCLAIMER
CMSC and PQHE present this information for educational purposes only. The content is provided solely by faculty who have been selected because of recognized expertise in their field. Participants have the professional responsibility to ensure that products are prescribed and used appropriately on the basis of their own clinical judgment and accepted standards of care. CMSC and PQHE, and the commercial supporter(s) assume no liability for the information herein.PRIVACY POLICY
Please review our privacy policy here: https://www.neuroserieslive.com/privacy-policy/.CONTACT INFORMATION
Accreditation and Technical Support:
For any technical issues or issues with your certificate, please contact NeuroSeriesLive at 877-394-1306 or at Support@NeuroSeriesLive.com.
